Figure 7.

In vivo screening of selected endogenous lipids for IOP lowering in different ocular hypertensive mouse models. Three different ocular hypertensive models were used. Cochlin and CTGF overexpression were achieved using viral expression vector. Myocilin mutant Y437H was a stable transgenic line. A, Cochlin overexpressor hypertensive model (n = 10), B, CTGF overexpression (n = 10) and C, myocilin mutant Y437H (n = 8). The lipids were evaluated for short time periods up to 15 d. Xalatan and Timolol were used for comparison. Topical application was carried out once daily and IOP was measured using a Tonolab 4‐6 h after application. *P ≤ .05 (t test compared to untreated control for each corresponding group)